Opexa Therapeutics Company Profile (NASDAQ:ACER)

About Opexa Therapeutics (NASDAQ:ACER)

Opexa Therapeutics logoAcer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACER
  • CUSIP: N/A
  • Web: www.opexatherapeutics.com
  • Market Cap: $13.17 million
  • Outstanding Shares: 739,000
Average Prices:
  • 50 Day Moving Avg: $14.05
  • 200 Day Moving Avg: $9.26
  • 52 Week Range: $5.18 - $36.76
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Return on Equity: -157.46%
  • Return on Assets: -106.61%
  • Current Ratio: 5.50%
  • Quick Ratio: 5.50%
  • Average Volume: 128,811 shs.
  • Beta: 2.28

Frequently Asked Questions for Opexa Therapeutics (NASDAQ:ACER)

What is Opexa Therapeutics' stock symbol?

Opexa Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Opexa Therapeutics' earnings last quarter?

Opexa Therapeutics, Inc. (NASDAQ:ACER) issued its quarterly earnings results on Friday, May, 12th. The company reported ($0.12) earnings per share for the quarter. View Opexa Therapeutics' Earnings History.

Who are some of Opexa Therapeutics' key competitors?

Who are Opexa Therapeutics' key executives?

Opexa Therapeutics' management team includes the folowing people:

  • Christopher Schelling, President, Chief Executive Officer, Director
  • Harry S. Palmin, Chief Financial Officer
  • William T. Andrews, Chief Medical Officer
  • Jason Amello, Director
  • Stephen J. Aselage, Director
  • Hubert Birner, Director
  • John M. Dunn, Director
  • Michelle Griffin, Director

How do I buy Opexa Therapeutics stock?

Shares of Opexa Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opexa Therapeutics' stock price today?

One share of Opexa Therapeutics stock can currently be purchased for approximately $18.57.

MarketBeat Community Rating for Opexa Therapeutics (NASDAQ ACER)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Opexa Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Opexa Therapeutics (NASDAQ:ACER) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A
Consensus Price Target History for Opexa Therapeutics (NASDAQ:ACER)
Price Target History for Opexa Therapeutics (NASDAQ:ACER)
Analysts' Ratings History for Opexa Therapeutics (NASDAQ:ACER)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/28/2016Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
10/28/2016Chardan CapitalDowngradeBuy -> NeutralN/AView Rating Details
10/28/2016AegisDowngradeBuy -> HoldN/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Opexa Therapeutics (NASDAQ:ACER)
Earnings by Quarter for Opexa Therapeutics (NASDAQ:ACER)
Earnings History by Quarter for Opexa Therapeutics (NASDAQ ACER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.12)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.25)($0.28)$0.73 millionViewN/AView Earnings Details
8/11/2016Q216($0.23)($0.30)$0.73 million$0.73 millionViewListenView Earnings Details
5/12/2016Q116($0.35)($0.31)$0.73 million$0.73 millionViewListenView Earnings Details
3/15/2016Q415($0.50)($2.05)$0.73 million$0.73 millionViewListenView Earnings Details
11/10/2015Q315($2.48)($0.42)$0.73 million$0.73 millionViewN/AView Earnings Details
8/12/2015Q215($0.08)($0.07)$0.73 millionViewListenView Earnings Details
5/12/2015Q1($0.15)($0.12)$0.38 millionViewListenView Earnings Details
11/6/2014($0.14)($0.12)$0.30 million$0.31 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.15)$0.30 million$0.31 millionViewN/AView Earnings Details
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details
11/14/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Opexa Therapeutics (NASDAQ:ACER)

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Opexa Therapeutics (NASDAQ:ACER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Opexa Therapeutics (NASDAQ:ACER)
Insider Ownership Percentage: 6.88%
Institutional Ownership Percentage: 36.35%
Insider Trades by Quarter for Opexa Therapeutics (NASDAQ:ACER)
Insider Trades by Quarter for Opexa Therapeutics (NASDAQ:ACER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2016Timothy C BarabeDirectorSell14,914$0.55$8,202.70View SEC Filing  
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Opexa Therapeutics (NASDAQ:ACER)
Latest Headlines for Opexa Therapeutics (NASDAQ:ACER)
Loading headlines, please wait.



Opexa Therapeutics (ACER) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.